Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Howard, Harry R."'
Autor:
Rama Y. Chandrasekaran, Jiri Aubrecht, Frederick R. Nelson, Linda A. Chatman, Hans Rollema, Frank M. Nedza, John M. Marcek, Philip A. Iredale, Jennifer B. Munzner, Betty Pettersen, Raggon Jeffrey W, David M. Rubitski, Julie Cianfrogna, Larry C. James, Karen W. Cook, Michael J. Banker, Diane F. Wong, Anne W. Schmidt, Michael Homiski, Howard Harry R, Daniel J. Lettiere, Butler Todd W, Scot Richard Mente, Jody Freeman, Travis T. Wager, Douglas K. Spracklin
Publikováno v:
Journal of Medicinal Chemistry. 54:7602-7620
The discovery of two histamine H3 antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in iden
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 15:1811-1815
A series of structurally related arylsulfonyl substituted 3-benzazepines displaying dopamine and serotonin antagonist activities, with pKi values in the range of 6.7 – 8.8, are disclosed in three applications from Glaxo. These compounds are claimed
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 15:1467-1470
Interest in the development of novel histamine H3 antagonists, especially for the treatment of obesity and CNS disorders, remains strong, as evidenced by recent patent activity from a large number of pharmaceutical companies. The present application
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 14:983-1008
Attention-deficit hyperactivity disorder (ADHD) is a psychological disorder affecting children and adolescents, whose symptoms often persist into the adult years, and is often effectively treated with stimulants. Recently, non-stimulant medications t
Publikováno v:
European Journal of Pharmacology. 425:197-201
Ziprasidone is a novel antipsychotic agent with a unique combination of pharmacological activities at human receptors. Ziprasidone has high affinity for human 5-HT receptors and for human dopamine D 2 receptors. Ziprasidone is a 5-HT 1A receptor agon
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 10:1549-1559
Attention deficit hyperactivity disorder (ADHD) is a syndrome that affects young children, manifesting itself through inappropriate behaviours and learning difficulties and persisting in many instances into adulthood. Treatment with stimulants, such
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 17:251-253
A novel series of 4-arylpiperidines and their salts, as well as their use in the treatment of CNS disorders, that is, depression, are disclosed. These compounds function as serotonin transporter (SERT) inhibitors and demonstrate significant activity
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 17:129-131
A group of structurally related thiazoloazepines displaying high affinity for histamine receptors of the H3 subtype, with pKi values in the range of 7.5 – 9.5, are disclosed in the latest of a series of such applications from Glaxo. These compounds
Autor:
Howard Harry R
Publikováno v:
Expert Opinion on Therapeutic Patents. 7:353-369
A sizeable number of new chemical entities designed to effectively treat acute and chronic schizophrenic behaviour have been disclosed in the patent literature during 1995 and 1996 and are discussed in this update. While the majority of these cases i
Autor:
Patrick R. Maloney, Frank E. Ewing, Howard Harry R, Celeste Johnson, Jean Morrone, M. E. Newman, Gwendolyn L. Robinson, Jackson Elisa Rose, Anne W. Schmidt, Stevin H. Zorn, Jerome S. Furman, Seeger Thomas Francis, John A. Lowe, Patricia A. Seymour
Publikováno v:
Journal of Medicinal Chemistry. 39:143-148
A series of substituted phenethyl derivatives of 3-benzisothiazolylpiperazine incorporating potent D2 and 5-HT2A antagonist activity was investigated as an approach to a novel atypical antipsychotic agent. The in vitro profile of 8e from this series